About this trial
Many consider laser enucleation of the prostate the new 'gold standard' for the surgical treatment of benign prostatic hyperplasia (BPH) due to its excellent outcomes, high success rates, and long-term efficacy. Holmium laser enucleation of the prostate (HoLEP) was the earliest form of prostate enucleation and is recommended by the American Urological Association (AUA), along with thulium laser enucleation of the prostate (ThuLEP), as size-independent techniques for the management of BPH with fewer complications than transurethral resection of the prostate (TURP). Further development of laser technology has additionally led to enucleation using pulsed-modulated (e.g. "Virtual Basket™" mode or MOSES™ mode) holmium lasers as well as the thulium fiber laser.
Eligibility criteria
Qualifiers
Understand and voluntarily sign an informed consent form.
Patients must be males with a prostate, at least 18 years of age
No prior prostate surgery
Disqualifiers
Unable/refuse to provide informed consent
Prior prostate surgery
Bladder stones that requiring lasering (small stone that can be removed whole is ok)
Unable to hold anticoagulants or antiplatelets per standard protocols for surgery and up to 1 week postop.
Trial design
Treatments tested in this trial
- holmium laser
- pulsed thulium laser
Treatment groups
Sponsors and collaborators
Smita De
Lead sponsor
The Cleveland Clinic
Sponsor institution